Support mood

The search closed in April 2018, before several cannabidiol-specific trials were published. The one anxiety signal the review did find came from pharmaceutical THC, in people whose main problem was chronic pain or multiple sclerosis, and was graded very low quality.

Every study pooled here watched people rather than assigning anything, so a flat curve may mark illness already underway rather than cause it. The slope was measured differently from study to study, from two saliva samples a day to six or more, which blurs the pooled figure.

Ninety-six volunteers across eleven groups is about nine per arm, so a null in any one arm means no effect was detected at that size, not that none exists. Digoxin is handled almost entirely by the drug pump rather than by the liver enzyme, so these results speak to one half of the mechanism.

Forty-two men across six arms leaves about seven per arm, so each arm's estimate is imprecise. The preparations were picked to span the hyperforin range rather than to represent what sits on a shelf. Every arm showed some induction, including the near-hyperforin-free one, so this is a slope rather than a safe threshold.

The trials disagree with each other far more than a pooled number suggests, with heterogeneity running to 89 percent, and the reviewers downgraded every headline estimate because of it. Smaller trials reported roughly double the benefit of larger ones. Trials from German-speaking countries, where the extracts are manufactured, reported results more favourable than trials from elsewhere.

The large US trial most often cited as proof that it fails in severe depression enrolled people its own authors described as moderately severe, so it did not test the question either. No trial has been designed with severity as the thing being varied.

Trial size stands in for several things at once, including how carefully a trial was run and who paid for it, so this does not isolate a single cause. The 2026 estimate rests on three trials in 207 people, all of one proprietary extract.

The 35,562-patient figure comes from post-marketing surveillance never designed to detect interactions, which duly reported none. The review's searches stopped in 2003. Its conclusion is explicitly conditional on a doctor knowing the patient is taking it, which is the condition most over-the-counter use fails.

Every trial ran between 4 and 12 weeks, so nothing here describes a year on either treatment. These are comparisons against antidepressants rather than against placebo, so the equivalence inherits whatever each trial's drug arm was worth. None of the trials was built to catch rare side effects.

The outcome is relapse, and in the underlying trials relapse was not reliably told apart from withdrawal. Slow means longer than four weeks, not the months-long schedules now advised. Venlafaxine was not separated from other antidepressants. The therapy comparison rests on two studies.

Each of these trials recruited a different population and measured a different outcome, so what they share is a pattern rather than one replicated result. Three of the four used large intermittent doses, a schedule some analyses argue is the least effective. In one of them, the group whose levels reached the recommended target fell more often than the group whose levels did not.

Eleven trials and 312 people in total, and the authors name the small number of studies as their main limitation. The search closed in August 2013 and nothing comparable has replaced it. No pooled dose is reported, so these results should not be read across to the intakes used in polycystic ovary syndrome supplements.

The subgroup finding that carries this claim is reported without a formal test of interaction, so it is suggestive rather than demonstrated. Six of the eighteen studies had no control group, and their effect sizes run two to three times larger, which is what an uncontrolled design predicts. Only 204 of the 1,408 participants were children or adolescents.

Eight healthy volunteers rather than people with HIV, and no clinical outcome was measured: resistance and treatment failure are inferences from the size of the drop, not events anyone observed here. A correction to the original report was published a year later and has never been reconciled with its figures.

The published abstract reports the pattern without the numbers, so this establishes that the variation is large without saying how large. The products were bought on the German market in 2001, and nothing here describes what is manufactured today.

The imatinib study used twelve healthy volunteers given single doses, not patients whose disease was being controlled. The irinotecan study had five patients and its 42 percent estimate runs anywhere from 14 to 70 percent. Neither measured whether any cancer did worse.

A guideline is an expert reading of the evidence with consensus in the loop, not a fresh analysis, and this one closes its evidence base in 2016. Its own authors name thin drug-interaction data as a caveat across the whole complementary-medicine section.

Eight men, no placebo arm, each compared against himself before and after. The same experiment in rats produced increases of two to nearly four-fold, so the animal figures are not the human ones and must never stand in for them. Gut expression came from biopsy; the liver claim rests on a breath test.

The two-week figure comes from a single follow-up measurement in ten patients, so it is a lower bound on how long the effect lasts rather than a measured rate of decay. The half-life figure was produced and published by an extract manufacturer, and its abstract never states how many volunteers it came from.

This comes from a reference monograph summarising other people's work rather than from primary research, with references last updated in 2020. Which constituent produces the antidepressant effect has never been established, and that is a far less settled question than which one drives the drug interactions.

The monograph states this qualitatively and names no country on either side, so it establishes that prescription status varies internationally without documenting where. Its references were last updated in 2020.

Sensitivity was measured on small patches of back skin under standardised lamps, which is a laboratory endpoint rather than sunburn in ordinary life. The two-week arm had no placebo group and compared each person against himself. Blood levels of hypericin, the constituent products are standardised on, did not track photosensitivity at all.

Everyone randomised had already responded during a six-week run-in, so the result describes people it was working for rather than anyone starting out. The significance test was one-sided. Two of the five authors are connected to the company that makes the extract.

Twenty-five healthy volunteers split across two arms, single-blind, and none of them was taking digoxin for a heart condition where a quarter would come off a therapeutic target. Two measured timepoints establish the direction and rough timescale of onset rather than a curve.

Nobody rejected in this study, because the doses were actively raised as the levels fell; it shows the size of the correction needed, not what follows when no one makes it. Ten patients, open-label, no control group, with each person compared against himself.

Trials of tapering exist for antidepressants as a class, so venlafaxine's share of that evidence is real but unlabelled. The registry count is from ClinicalTrials.gov alone. The guideline review closed in May 2021, before the UK guideline of 2022 added its schedule; the label's schedule is the one its trials happened to use.

A report count is not a rate: it says withdrawal made up a large share of a drug's reports, not how many users had it. The drugs with the strongest signals were also the most reported and most talked about, which the authors say may inflate their ratios. Among 19 people who had once stopped fluoxetine, a drug that lingers for weeks, remembered withdrawal was as severe as after venlafaxine.

One trial of 103 people, with venlafaxine pooled among drugs of its class and prediction intervals wide enough that the 29% could be anywhere from 8% to 72%. Taper lengths were chosen by the clinic. Whether withdrawal causes relapse or the two share a cause is not settled by this design.

Twenty-three of the 61 reports were single case reports, and no pooled figure exists for how many people get a prolonged course. The label's drawn-out cases come from voluntary reports with no denominator. NICE puts the usual course at one to two weeks, occasionally months.

Every one of these measured what people said or reported, not a biological marker, so the pattern could reflect reporting as much as experience. The reporting-database figure has no denominator of users. None separates venlafaxine from other antidepressants.

Only 155 people took part, so a small real effect could hide inside that. Entry required a level in the insufficient band rather than severe deficiency, which leaves open whether people much further down would respond. What makes the result carry more than its size suggests is that not one of nine outcomes moved in either direction.

The authors state plainly that the study lacked the statistical power to answer its own question. Depression was diagnosed against structured criteria at in-person assessments, which is a real strength, but too few cases arose for that rigour to help. A result this imprecise is an absence of evidence, not evidence of absence.

Everyone studied already had normal B12, so this says nothing about people who are actually short of it. Several of the pooled trials gave B12 inside a B complex alongside folate, so the B12-only signal rests on fewer studies. The fatigue gap is an absence of trials, not a pooled null.

Five of the eight authors work for the company that makes the extract and two more for the contract research organisation that ran the study. The design was open-label, non-randomised and single-sequence, in 20 people. The result belongs to this one proprietary extract, not to St John's Wort products in general, most of which carry far more hyperforin.

The six preparations were selected to span the hyperforin range, so the gap between them is wider than a random pair off a shelf would be. About seven men per arm. How far real products vary has been shown to be large but has never been given a number.

Both trials tested a single extract at a single dose, so neither says anything about preparations that differ in strength. The 340-person trial reports no trend toward benefit whatsoever, which an insensitive trial would not be guaranteed to produce. The smaller trial enrolled about a quarter fewer people than it planned to.

Two large US trials found no benefit where pooled trials find one, but in both the prescription antidepressant also failed to beat placebo. The open question is whether those trials could detect any effect at all.

The participants skewed middle-aged and older, and most were women. A long list of outcomes was tested at once, which on its own makes some of the positive ones likely to be chance.

Almost nobody in the trial was depressed at the start, so this tests whether vitamin D3 stops depression arriving, not whether it treats depression already present. Participants were not selected for low vitamin D either. Several of the authors declare payments from supplement companies, which the paper states.

Large trials found no mood benefit; the pooled benefit rests on small, short trials, some counted twice. What observational studies still cannot separate is whether low vitamin D brings on depression or depression keeps people indoors.

A pooled stress effect of nearly six standard deviations would mean almost nobody on placebo scored as low as anyone on ashwagandha, while earlier trials of the herb measured effects of 0.63 to 0.74 standard deviations. The authors themselves note the trials differed widely, and pooling very different trials can produce a size no single trial supports. The dose-response finding is read off the same pooling.

How much ashwagandha eases stress is unsettled. The poolings agree that it helps, but the largest reports an effect several times what single trials measured, and nothing yet explains the gap.

Only the positive trial tends to get quoted. The dose difference is the authors' own explanation for the split, but it is a comparison across two separate studies rather than a randomised test of dose, and the trial that worked had 75 patients. The 15mg used is roughly forty times a periconceptional folate dose and is a prescription medical food in the United States, not the supplement sold to consumers on the same reasoning.

Seven trials and 325 people is a thin base, and the authors ask for larger, better ones before anybody draws a clinical conclusion. An effect this big out of a pool this small is also the pattern produced when small trials that found nothing never reach publication. Magnesium was compared with placebo, never with a prescription antidepressant.

Every trial gave the capsules alongside antidepressants rather than instead of them, so what was measured is an add-on effect. The EPA-heavy figure rests on a smaller set of trials than the overall one, which makes it the top of a range rather than a settled number. A correction to this analysis was published two years afterwards, so its exact figures are worth re-checking. Depression trials also carry a strong placebo response, which pushes small differences around.

Seventeen women, and although none ovulated, a study this small could not have detected a modest rise in ovulation if there were one. Bleeding was recorded by diary. The hyperforin content of the preparation was never reported, and that is the variable later work shows decides the size of the effect.

Whether St John's Wort lets ovulation break through a combined pill is unsettled. In both trials the pill's hormone levels fell and bleeding rose, but they split on ovulation, and none measured pregnancy.

Spontaneous reporting can establish that an interaction happens in practice but never how often, and it skews toward the severe and the newsworthy. The regulator's review closed in 2002, before the work showing that hyperforin content decides how strongly any given preparation induces anything.

Whether St John's Wort taken with serotonin-acting antidepressants or migraine triptans risks serotonin syndrome rests on case reports, which show it can happen but not how often. No controlled study has tested either pairing.

The review naming it does not state the size or even the direction of the effect for St John's Wort specifically, and its classification of 78 items leans heavily on case reports of varying quality. Warfarin is monitored by routine blood test, so the practical risk is a result drifting between checks rather than a failure nobody sees.

The argument comes from imaging of SSRIs, not venlafaxine, and from receptor occupancy rather than from a trial that measured how people felt. No randomised trial has compared hyperbolic with straight-line tapering of venlafaxine.

Nobody tapered without the strips for comparison, so the figures describe the users, not the strips' effect. Response rates were 48% and 59%, and outcomes were self-reported, some recalled from up to five years earlier. The authors' institute received a grant from the pharmacy that makes the strips.

The three dose figures are second-hand: a 2022 review copied them from a 2005 UK regulator's report, and the report itself is where the counts live. The middle dose came out lower than the lowest, so the rise rests on the 150 mg group alone. The label gives the trend and no number.

The survey reached 18% of those invited, all recalling past attempts, which plausibly inflates every figure, and it did not separate venlafaxine from other antidepressants. The tenfold odds ratio ran from about 3 to 38. The label states the trend without a number. The tapering cohort had no comparison group.

Whether years on venlafaxine make it harder to stop is open. The label and long-term users say yes; the trials that say no lasted only weeks, so they never tested the question.

The percentages were extracted by a later review from the trial's tables; the trial's own summary gives only the direction. Withdrawal was a side outcome of a trial built to compare how well the drugs worked, after eight weeks of use, so it says nothing about longer use. A review of 61 reports found withdrawal most often with venlafaxine but could give no pooled figure.

The trial's taper lengths were chosen by the clinic, not randomised, and ran weeks. The cohort had no group tapering without the strips, and the 608 who rated symptoms daily were a self-selected minority of 3,956 users, most of whom had failed before. The cohort's authors developed the strips.

Whether a slower venlafaxine taper spares withdrawal is unsettled. A cohort that chose slow tapering says yes, a trial with few-week tapers says no, and neither tested the months-long schedule now recommended.